PMPRB releases proposed amendment to Interim Guidance for co

On June 20, 2023, the Patented Medicine Prices Review Board (PMPRB) released a proposal to amend the Interim Guidance, which sets out the approach for reviewing the prices of patented...

Related Keywords

Canada , Novo Nordisk , Thomasj Digby , National Prescription Drug Utilization Information System , Patented Medicine Prices Review Board , Interim Guidance , Patented Medicines Regulations , Maximum Average Potential Price , Non Excessive Average Price , Chairperson Thomas , Market Intelligence Report , Antidiabetic Drugs ,